Amgen And Servier Announce Product Collaboration

               Amgen And Servier Announce Product Collaboration

Amgen Obtains US Rights to Novel EU-Approved Cardiovascular Therapy; Servier
Receives Option for Omecamtiv Mecarbil in Europe

PR Newswire

THOUSAND OAKS, Calif., and SURESNES, France, July 9, 2013

THOUSAND OAKS, Calif., and SURESNES, France, July 9, 2013 /PRNewswire/
--Amgen (NASDAQ:AMGN) and Servier today announced a new collaboration
agreement leveraging each company's commitment to cardiovascular disease.

Under the terms of the agreement, Amgen has obtained commercial rights in the
U.S. to Servier's novel oral drug, approved in the EU as Procoralan®
(ivabradine), for chronic heart failure and stable angina in patients with
elevated heart rates. Amgen has also received an exclusive option to develop
and commercialize Servier's investigational molecule, S38844, for
cardiovascular diseases in the U.S. Currently, S38844 is in Phase 2 studies
for the treatment of heart failure. Through the collaboration, Servier has
obtained rights to commercialize omecamtiv mecarbil in Europe. Omecamtiv
mecarbil is an activator of cardiac myosin, which is currently being tested
for potential applications in the treatment of heart failure in patients with
systolic dysfunction.

Both companies can exercise their respective options for the investigational
therapies up to completion of certain Phase 2 studies. Under the terms of the
agreement, Amgen will make a one-time $50 million upfront payment and future
milestone and royalty payments for ivabradine. Financial terms associated with
Amgen's option for S38844 and Servier's option for omecamtiv mecarbil were not
disclosed.

"Amgen is pleased to enter into this collaboration with Servier to bring
potential new cardiovascular treatment options to patients in both the U.S.
and Europe," said Sean E. Harper, M.D., executive vice president of Research
and Development at Amgen. "A critical unmet medical need remains for patients
who don't respond adequately to current available therapies for heart failure
and angina. Ivabradine, an If inhibitor, offers a novel alternative approach
for patients with elevated heart rates. We value Servier's extensive
experience in cardiovascular disease and look forward to working with them as
Amgen continues to build our presence in this area."

"Servier is very pleased to establish a collaboration with Amgen, a leading
biotechnology company with a unique track record of bringing innovative
medicines to patients. This is a clear recognition of the medical value of
ivabradine, one of our major cardiovascular innovations, which could also
benefit U.S. patients," said Jean-Philippe Seta, M.D., chief executive officer
at Servier.

"Ivabradine is a first-in-class innovative drug for the treatment of heart
failure and angina. The clinical benefit and safety profile are supported by
the results of clinical studies performed or being performed in more than
40,000 patients. I strongly believe that Servier's expertise in heart failure
will complement Amgen's efforts in making omecamtiv mecarbil, a very
innovative and complementary approach to treating heart failure, available to
patients in Europe," said Emmanuel Canet, M.D., Ph.D., head of Research and
Development at Servier.

Ivabradine is an If inhibitor approved by the European Medicines Agency in
2005 for the symptomatic treatment of stable angina and in 2012 for chronic
heart failure, as well as approved in more than 100 other countries, excluding
the U.S. Omecamtiv mecarbil activates cardiac muscle contractility and
operates to strengthen heart function in patients with systolic dysfunction.
Omecamtiv mecarbil is in Phase 2 studies and is being developed under a
collaboration between Cytokinetics and Amgen.

About Amgen
Amgen discovers, develops, manufactures and delivers innovative human
therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first
companies to realize the new science's promise by bringing safe, effective
medicines from lab to manufacturing plant to patient. Amgen therapeutics have
changed the practice of medicine, helping people around the world in the fight
against serious illnesses. With a deep and broad pipeline of potential new
medicines, Amgen remains committed to advancing science to dramatically
improve people's lives. For more information, visit www.amgen.comand follow
us on www.twitter.com/amgen.

About Servier
Servier is a privately-run French research-based pharmaceutical company.
Current therapeutic domains for Servier medicines are cardiovascular,
metabolic, neurological, psychiatric and bone and joint diseases, as well as
oncology. Servier is established in 140 countries worldwide with over 20,000
employees and a 2012 turnover of €3.9 billion. Servier invests 25% of its
turnover in R&D. More information is available at: http://www.servier.com 

Amgen Forward-Looking Statements
This news release contains forward-looking statements that are based on
Amgen's current expectations and beliefs and are subject to a number of risks,
uncertainties and assumptions that could cause actual results to differ
materially from those described. All statements, other than statements of
historical fact, are statements that could be deemed forward-looking
statements, including estimates of revenues, operating margins, capital
expenditures, cash, other financial metrics, expected legal, arbitration,
political, regulatory or clinical results or practices, customer and
prescriber patterns or practices, reimbursement activities and outcomes and
other such estimates and results. Forward-looking statements involve
significant risks and uncertainties, including those discussed below and more
fully described in the Securities and Exchange Commission (SEC) reports filed
by Amgen, including Amgen's most recent annual report on Form 10-K and any
subsequent periodic reports on Form 10-Q and Form 8-K. Please refer to Amgen's
most recent Forms 10-K, 10-Q and 8-K for additional information on the
uncertainties and risk factors related to Amgen's business. Unless otherwise
noted, Amgen is providing this information as of July 9, 2013, and expressly
disclaims any duty to update information contained in this news release.

No forward-looking statement can be guaranteed and actual results may differ
materially from those Amgen projects. Discovery or identification of new
product candidates or development of new indications for existing products
cannot be guaranteed and movement from concept to product is uncertain;
consequently, there can be no guarantee that any particular product candidate
or development of a new indication for an existing product will be successful
and become a commercial product. Further, preclinical results do not guarantee
safe and effective performance of product candidates in humans. The complexity
of the human body cannot be perfectly, or sometimes, even adequately modeled
by computer or cell culture systems or animal models. The length of time that
it takes for Amgen to complete clinical trials and obtain regulatory approval
for product marketing has in the past varied and Amgen expects similar
variability in the future. Amgen develops product candidates internally and
through licensing collaborations, partnerships and joint ventures. Product
candidates that are derived from relationships may be subject to disputes
between the parties or may prove to be not as effective or as safe as Amgen
may have believed at the time of entering into such relationship. Also, Amgen
or others could identify safety, side effects or manufacturing problems with
Amgen's products after they are on the market. Amgen's business may be
impacted by government investigations, litigation and product liability
claims. If we fail to meet the compliance obligations in the corporate
integrity agreement between us and the U.S. government, we could become
subject to significant sanctions. Amgen depends on third parties for a
significant portion of its manufacturing capacity for the supply of certain of
its current and future products and limits on supply may constrain sales of
certain of its current products and product candidate development.

In addition, sales of Amgen's products are affected by the reimbursement
policies imposed by third-party payers, including governments, private
insurance plans and managed care providers and may be affected by regulatory,
clinical and guideline developments and domestic and international trends
toward managed care and healthcare cost containment as well as U.S.
legislation affecting pharmaceutical pricing and reimbursement. Government and
others' regulations and reimbursement policies may affect the development,
usage and pricing of Amgen's products. In addition, Amgen competes with other
companies with respect to some of its marketed products as well as for the
discovery and development of new products. Amgen believes that some of its
newer products, product candidates or new indications for existing products,
may face competition when and as they are approved and marketed. Amgen's
products may compete against products that have lower prices, established
reimbursement, superior performance, are easier to administer, or that are
otherwise competitive with its products. In addition, while Amgen routinely
obtains patents for its products and technology, the protection offered by its
patents and patent applications may be challenged, invalidated or circumvented
by its competitors and there can be no guarantee of Amgen's ability to obtain
or maintain patent protection for its products or product candidates. Amgen
cannot guarantee that it will be able to produce commercially successful
products or maintain the commercial success of its existing products. Amgen's
stock price may be affected by actual or perceived market opportunity,
competitive position, and success or failure of its products or product
candidates. Further, the discovery of significant problems with a product
similar to one of Amgen's products that implicate an entire class of products
could have a material adverse effect on sales of the affected products and on
Amgen's business and results of operations.

The scientific information discussed in this news release related to product
candidates is preliminary and investigative. Such product candidates are not
approved by the U.S. Food and Drug Administration (FDA) or other regulatory
authorities, and no conclusions can or should be drawn regarding the safety or
effectiveness of the product candidates. Only the FDA or other regulatory
authorities can determine whether the product candidates are safe and
effective for the use(s) being investigated. Further, the scientific
information discussed in this news release relating to new indications for
products is preliminary and investigative and is not part of the labeling
approved by the FDA or other regulatory authorities for the products. The
products are not approved for the investigational use(s) discussed in this
news release, and no conclusions can or should be drawn regarding the safety
or effectiveness of the products for these uses. Only the FDA or other
regulatory authority can determine whether the products are safe and effective
for these uses. Healthcare professionals should refer to and rely upon the
approved labeling for the products, and not the information discussed in this
news release.

CONTACT:

Amgen, Thousand Oaks
Ashleigh Koss, 805-313-6151 (media)
Arvind Sood, 805-447-1060 (investors)

Servier Communication Department
+ 33 (0)1 55 72 60 37 presse@servier.fr

(Logo: http://photos.prnewswire.com/prnh/20081015/AMGENLOGO)

(Logo: http://photos.prnewswire.com/prnh/20130708/LA44084LOGO)

SOURCE Amgen; Servier

Website: http://www.amgen.com
Website: http://www.servier.com